Adaptimmune Therapeutics PLC: Adaptimmune Announces 70% of People with Advanced Synovial Sarcoma Who Respond to Afami-cel are Alive Two Years Post-Treatment; Data from Cohort 1 of SPEARHEAD-1 to be Presented at ASCO

Approximately 39% of patients had clinical responses after a single dose of afami-cel in Cohort 1 of the pivotal SPEARHEAD-1 trial and the median duration of response was ~12 months (CTOS 2022)Median

Related Keywords

Gewinn Nur ,Dana Lynch ,Dennis Williams ,Julip Miller ,John Charlson ,College Of Wisconsin ,Exchange Commission ,Stage Development ,Corporate Affairs ,Corporate Communications ,Medical College ,Late Stage Development ,Biologics License Application ,Orphan Drug Designation ,Regenerative Medicine Advanced Therapy ,Specific Peptide Enhanced Affinity Receptor ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,Senior Director ,Adaptimmune ,Herapeutics ,Nnounces ,People ,Dvanced ,Synovial ,Tarcoma ,Espond ,Yfami ,Live ,Tears ,Most ,Treatment ,Data ,Rom ,Cohort ,Spearhead ,Resented ,Disco ,